OpenURL Connection Search

Select item for more details and to access through your institution.

Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab.
Published in:
PLoS ONE, 2013, v. 8, n. 2, p. 1, doi. 10.1371/journal.pone.0056112
By:
- Ather, Ferdows;
- Hamidi, Habib;
- Fejzo, Marlena S.;
- Letrent, Stephen;
- Finn, Richard S.;
- Kabbinavar, Fairooz;
- Head, Christian;
- Wong, Steven G.
Publication type:
Article
SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma.
Published in:
Cancers, 2023, v. 15, n. 3, p. 906, doi. 10.3390/cancers15030906
By:
- Gordon, Erlinda Maria;
- Chawla, Sant P.;
- Tellez, Walter Andree;
- Younesi, Elan;
- Thomas, Sonu;
- Chua-Alcala, Victoria S.;
- Chomoyan, Hripsime;
- Valencia, Chrysler;
- Brigham, Don Arlen;
- Moradkhani, Ania;
- Quon, Doris;
- Srikureja, Amornchit;
- Wong, Steven G.;
- Tseng, William;
- Federman, Noah
Publication type:
Article
Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells.
Published in:
Nucleic Acids Research, 1999, v. 27, n. 20, p. 4008
By:
- Oh, Juliana J.;
- Grosshans, David R.;
- Wong, Steven G.;
- Slamon, Dennis J.;
- Bargmann, C.I.;
- Slamon, D.J.;
- O’Reilly, S.M.;
- Press, M.F.;
- Seshadri, R.;
- Shih, C.;
- Di Fiore, P.P.;
- Hudziak, R.M.;
- Pietras, R.J.;
- Pegram, M.D.;
- Chazin, V.R.;
- St John, T.P.;
- Chirgwin, J.M.;
- Sambrook, J.;
- Waseem, A.;
- Oshima, R.G.
Publication type:
Article
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Published in:
Cancer (0008543X), 2014, v. 120, n. 5, p. 692, doi. 10.1002/cncr.28477
By:
- Grivas, Petros D.;
- Daignault, Stephanie;
- Tagawa, Scott T.;
- Nanus, David M.;
- Stadler, Walter M.;
- Dreicer, Robert;
- Kohli, Manish;
- Petrylak, Daniel P.;
- Vaughn, David J.;
- Bylow, Kathryn A.;
- Wong, Steven G.;
- Sottnik, Joseph L.;
- Keller, Evan T.;
- Al‐Hawary, Mahmoud;
- Smith, David C.;
- Hussain, Maha
Publication type:
Article
Carbonic Anhydrase IX in Bladder Cancer: A Diagnostic, Prognostic, and Therapeutic Molecular Marker.
Published in:
Cancer (0008543X), 2009, v. 115, n. 7, p. 1448, doi. 10.1002/cncr.24163
By:
- Kiatte, Tobias;
- Seligson, David B.;
- Jian Yu Rao;
- Hong Yu;
- de Martino, Michela;
- Kawaoka, Kelly;
- Wong, Steven G.;
- Belidegrun, Arie S.;
- Pantuck, Allan J.
Publication type:
Article

Found: 5

Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab.

SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma.

Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells.

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.

Carbonic Anhydrase IX in Bladder Cancer: A Diagnostic, Prognostic, and Therapeutic Molecular Marker.